DNA

£7.5 million Longitude Prize on ALS launches

LONDON, June 25, 2025 /PRNewswire/ -- The Longitude Prize on ALS, a £7.5 million global challenge prize, has launched to…

6 months ago

Zymo Research Unveils MultiOmiX Workstation with Show-Stopping Launch at ASM Microbe 2025

IRVINE, Calif., June 24, 2025 /PRNewswire/ -- Zymo Research stole the spotlight at the American Society for Microbiology (ASM) Microbe 2025…

6 months ago

A Glimpse Into the Future of Mass Spectrometry: Game-Changing Technologies and Transformative Trends Unveiled at ASMS 2025

ARLINGTON, Va., June 24, 2025 /PRNewswire/ -- Behind the doors of the ASMS 2025 conference, held this June in Baltimore, the…

6 months ago

PAVmed Subsidiary Veris Health Completes $2.5 Million Direct Equity Financing

Private placement yields $2.5 million from the sale of Veris Health common stock at a $35 million pre-money valuation. NEW…

6 months ago

Lexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA Therapeutics

Up to $40 Million Private Equity Financing into a New Entity Addressing Cardiac Genetic Diseases that Existing AAV Platforms are…

6 months ago

Enzo Biochem, Inc. To be Acquired by Battery Ventures in All-Cash Transaction

Transaction Follows Completion of Comprehensive Strategic Review by Special Committee of the Board to Maximize Shareholder Value Farmingdale, NY, June…

6 months ago

Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company’s multiomics strategy

Combines highly complementary proteomics expertise with Illumina's industry-leading product innovation and global market reach Positions Illumina to achieve growth in…

6 months ago

Beyond Medical Technologies Closes Second Tranche of Convertible Note Financing

Vancouver, British Columbia--(Newsfile Corp. - June 23, 2025) - Beyond Medical Technologies Inc. (CSE: DOCT) (FSE: 7FM) (OTC Pink: DOCKF)…

6 months ago

Novo Nordisk’s subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025

Subcutaneous amycretin phase 1b/2a data on the safety, tolerability and weight loss potential in people with overweight or obesity was…

6 months ago

Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO

Phase 2 highlights robust biomarker identification and survival correlations in first-line metastatic pancreatic cancer (mPDAC) treated with elraglusibCHICAGO and FORT…

6 months ago